文献速递乳腺MRUS

MRI 上无强化的可能良性超声肿块能否避免随访

Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI?
PubMed 文献 · Eur Radiol · 2020-09-01

回顾性纳入 2010—2018 年新诊断乳腺癌女性,分析超声评估为 BI-RADS 3 或 4 且于超声后 90 天内行双侧增强乳腺 MRI 的额外肿块。309 个肿块中 140 个(45%)MRI 无强化,对应 105 例患者,全部为良性,MRI 无强化对恶性肿块的阴性预测值为 100%(95%CI 96.7–100.0)。

要点

  • 超声 BI-RADS 3 或 4 的额外肿块若在治疗前 MRI 上无强化,本研究中均为良性。
  • MRI 无强化对超声可疑肿块的阴性预测值为 100%(95%CI 96.7–100.0)。
  • 作者认为若回顾性更新初始超声 BI-RADS 评估,可能减少不必要的随访影像和/或活检。

诊断标准与关键数值

  • 309 个额外肿块中 140/309(45%)在 MRI 上无强化,169/309(55%)有强化。
  • 140 个无强化肿块见于 105 例女性(平均年龄 54 岁,范围 28–82 岁),全部为良性(140/140,100%)。
  • 140 个良性无强化肿块中 89/140(63.6%)经病理证实,51/140(36.4%)显示至少 2 年影像学稳定。
  • 治疗前 MRI 显示超声肿块对应灶无强化,其阴性预测值为 100%(95%CI 96.7–100.0),按患者水平计算。

临床应用与阅片要点

  • 作者认为,若回顾性更新初始超声 BI-RADS 评估和管理建议,由转诊医生开具 MRI 可能减少不必要的随访影像和/或活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To assess whether no enhancement on pre-treatment MRI can rule out malignancy of additional US mass(es) initially assessed as BI-RADS 3 or 4 in women with newly diagnosed breast cancer.

METHODS: This retrospective study included consecutive women from 2010-2018 with newly diagnosed breast cancer; at least one additional breast mass (distinct from index cancer) assigned a BI-RADS 3 or 4 on US; and a bilateral contrast-enhanced breast MRI performed within 90 days of US. All malignant masses were pathologically proven; benign masses were pathologically proven or defined as showing at least 2 years of imaging stability. Incidence of malignant masses and NPV were calculated on a per-patient level using proportions and exact 95% CIs.

RESULTS: In 230 patients with 309 additional masses, 140/309 (45%) masses did not enhance while 169/309 (55%) enhanced on MRI. Of the 140 masses seen in 105 women (mean age, 54 years; range 28-82) with no enhancement on MRI, all had adequate follow-up and 140/140 (100%) were benign, of which 89/140 (63.6%) were pathologically proven and 51/140 (36.4%) demonstrated at least 2 years of imaging stability. Pre-treatment MRI demonstrating no enhancement of US mass correlate(s) had an NPV of 100% (95% CI 96.7-100.0).

CONCLUSIONS: All BI-RADS 3 and 4 US masses with a non-enhancing correlate on pre-treatment MRI were benign. The incorporation of MRI, when ordered by the referring physician, may decrease unnecessary follow-up imaging and/or biopsy if the initial US BI-RADS assessment and management recommendation were to be retrospectively updated.

KEY POINTS: • Of 309 BI-RADS 3 or 4 US masses with a corresponding mass on MRI, 140/309 (45%) demonstrated no enhancement whereas 169/309 (55%) demonstrated enhancement • All masses classified as BI-RADS 3 or 4 on US without enhancement on MRI were benign • MRI can rule out malignancy in non-enhancing US masses with an NPV of 100.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Avendano D, Marino MA, Onishi N, et al. Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI? Eur Radiol. 2020. PMID: 32870394. doi:10.1007/s00330-020-07216-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。